Literature DB >> 32407712

Suppression of cathepsin a inhibits growth, migration, and invasion by inhibiting the p38 MAPK signaling pathway in prostate cancer.

Song Park1, Wookbong Kwon2, Jin-Kyu Park3, Su-Min Baek3, Seoung-Woo Lee3, Gil-Jae Cho3, Yun-Sok Ha4, Jun Nyung Lee4, Tae Gyun Kwon4, Myoung Ok Kim5, Zae Young Ryoo6, Se-Hyeon Han7, Jee Eun Han8, Seong-Kyoon Choi9.   

Abstract

Prostate cancer has the highest incidence among men in advanced countries, as well as a high mortality rate. Despite the efforts of numerous researchers to identify a gene-based therapeutic target as an effective treatment of prostate cancer, there is still a need for further research. The cathepsin gene family is known to have a close correlation with various cancer types and is highly expressed across these cancer types. This study aimed at investigating the correlation between the cathepsin A (CTSA) gene and prostate cancer. Our findings indicated a significantly elevated level of CTSA gene expression in the tissues of patients with prostate cancer when compared with normal prostate tissues. Furthermore, the knockdown of the CTSA gene in the representative prostate cancer cell lines PC3 and DU145 led to reduced proliferation and a marked reduction in anchorage-independent colony formation, which was shown to be caused by cell cycle arrest in the S phase. In addition, CTSA gene-knockdown prostate cancer cell lines showed a substantial decrease in migration and invasion, as well as a decrease in the marker genes that promote epithelial mesenchymal transition (EMT). Such phenotypic changes in prostate cancer cell lines through CTSA gene suppression were found to be mainly caused by reduced p38 MAPK protein phosphorylation; i.e. the inactivation of the p38 MAPK cell signaling pathway. Tumorigenesis was also found to be inhibited in CTSA gene-knockdown prostate cancer cell lines when a xenograft assay was carried out using Balb/c nude mice, and the p38 MAPK phosphorylation was inhibited in tumor tissues. Thus, the CTSA gene is presumed to play a key role in human prostate cancer tissues through high-level expression, and the suppression of the CTSA gene leads to the inhibition of prostate cancer cell proliferation, colony formation, and metastasis. The mechanism, by which these effects occur, was demonstrated to be the inactivation of the p38 MAPK signaling pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cathepsin A; Cell cycle; Metastasis; Prostate cancer; p38 MAPK

Year:  2020        PMID: 32407712     DOI: 10.1016/j.abb.2020.108407

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  5 in total

1.  High cathepsin A protein expression predicts poor prognosis and tumor recurrence of hepatocellular carcinoma patients after curative hepatectomy.

Authors:  Laibang Luo; Xuyang Wang; Huaxiang Wang; Chengkai Yang; Youfu Zhang; Xinchang Li; Zhidan Xu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 2.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

3.  Indolethylamine-N-Methyltransferase Inhibits Proliferation and Promotes Apoptosis of Human Prostate Cancer Cells: A Mechanistic Exploration.

Authors:  Wang Jianfeng; Wang Yutao; Bi Jianbin
Journal:  Front Cell Dev Biol       Date:  2022-02-17

4.  Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy.

Authors:  Chao Luo; Songzhe He; Haibo Zhang; Shuhua He; Huan Qi; Anyang Wei
Journal:  Front Genet       Date:  2022-02-02       Impact factor: 4.599

5.  Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma.

Authors:  Huaxiang Wang; Fengfeng Xu; Fang Yang; Lizhi Lv; Yi Jiang
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.